Comparison of New Fractures after Treatment with Alendronate or Raloxifene in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation
- Author:
Jeong Ho SEO
1
;
Kyu Yeol LEE
;
Ki Woong KIM
;
Hyun Ho KIM
Author Information
1. Department of Orthopedic Surgery, College of Medicine, Dong-A University, Busan, Korea. gylee@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Osteoporosis;
Compression fracture;
Alendronate;
Raloxifene
- MeSH:
Alendronate;
Fractures, Compression;
Humans;
Incidence;
Kyphoplasty;
Osteoporosis;
Raloxifene Hydrochloride;
Spine;
Vertebroplasty
- From:Journal of Korean Society of Osteoporosis
2014;12(3):117-123
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUNDS: The purpose of this study was to examine the incidence of new fractures after treatment with alendronate or raloxifene in patients with compression fractures treated with cement augmentation. METHODS: 140 patients with compression fracture treated with vertebroplasty or kyphoplasty between January 2007 and January 2013 were divided into 3 groups, an unmedicated group (n=31), an alendronate group (n=49), and a raloxifene group (n=60). The incidence of new fractures in 3 groups were investigated. RESULTS: The incidence of new fractures was 29% (9 cases) in unmedicated group, 20% (10 case) in alendronate group, and 26% (16 case) in raloxifene group. Average period to new fracture was 16.2 months in alendronate group and 21.5 months in raloxifene group. CONCLUSIONS: After treatment with alendronate or raloxifene, BMD increased and incidence of new fractures decreased in patients with osteoporotic compression fracture treated with vertebroplasty or kyphoplasty. Patients with alendronate showed numerical improvement in BMD and incidence of new fractures than raloxifene. But, incidence of new fractures in spine and other site showed no statisically significant.
